Cover Page - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Mar. 07, 2025 |
Jun. 30, 2024 |
|
| Cover [Abstract] | |||
| Document Type | 10-K/A | ||
| Document Annual Report | true | ||
| Document Period End Date | Dec. 31, 2024 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Document Transition Report | false | ||
| Entity File Number | 001-38085 | ||
| Entity Registrant Name | Ovid Therapeutics Inc. | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Tax Identification Number | 46-5270895 | ||
| Entity Address, Address Line One | 441 Ninth Avenue, 14th Floor | ||
| Entity Address, City or Town | New York | ||
| Entity Address, State or Province | NY | ||
| Entity Address, Postal Zip Code | 10001 | ||
| City Area Code | 646 | ||
| Local Phone Number | 661-7661 | ||
| Title of 12(b) Security | Common Stock, par value $0.001 per share | ||
| Trading Symbol | OVID | ||
| Security Exchange Name | NASDAQ | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 45.9 | ||
| Entity Common Stock, Shares Outstanding | 71,109,514 | ||
| Documents Incorporated by Reference | None
|
||
| Amendment Description | Ovid Therapeutics Inc. (the “Company”) is filing this Amendment No. 1 to its Annual Report on Form 10-K (“Amendment”), originally filed with the Securities and Exchange Commission (the “SEC”) on March 11, 2025 (the “Initial Filing”), to include the information required by Items 10 through 14 of Part III of the Annual Report on Form 10-K. We are filing this Amendment to include Part III information in our Form 10-K because the Company’s definitive proxy statement will not be filed within 120 days after the end of the fiscal year covered by the Company’s Annual Report on Form 10-K.In addition, Item 15 of the Initial Filing has also been amended to reflect the filing of the new certifications of its principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Since no new financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Because no financial statements are contained within this Amendment, the Company is not including certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.Except as contained herein, this Amendment does not modify or update disclosures contained in the Initial Filing. This Amendment should be read in conjunction with the Company’s other filings made with the SEC subsequent to the date of the Initial Filing.In this Amendment, unless the context requires otherwise, all references to “we,” “our,” “us,” “Ovid” and the “Company” refer to Ovid Therapeutics Inc. | ||
| Amendment Flag | true | ||
| Entity Central Index Key | 0001636651 | ||
| Document Fiscal Year Focus | 2024 | ||
| Document Fiscal Period Focus | FY |
Audit Information |
12 Months Ended |
|---|---|
Dec. 31, 2024 | |
| Auditor Information [Abstract] | |
| Auditor Firm ID | 185 |
| Auditor Name | KPMG LLP |
| Auditor Location | New York, NY |
Award Timing Disclosure $ / shares in Units, shares in Thousands |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Sep. 09, 2024
USD ($)
shares
$ / shares
|
Jul. 30, 2024
USD ($)
shares
$ / shares
|
|
| Award Timing Disclosures [Line Items] | |||
| Award Timing MNPI Disclosure | From time to time, we grant stock options to employees, including our named executive officers. Historically, we have granted new-hire option awards on or soon after a new hire’s employment start date and annual refresh employee option grants in the first quarter of each fiscal year, which refresh grants are typically approved at the regularly scheduled meeting of the Compensation Committee occurring in such quarter. Non-employee directors receive automatic grants of initial and annual stock option awards, at the time of a director’s initial appointment or election to the board and at the time our Board or Compensation Committee grants annual equity awards to our executive officers and other employees, respectively, pursuant to the non-employee director compensation policy, as further described under the heading, “Director Compensation—Cash and Equity Compensation” above. We do not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features. The Compensation Committee considers whether there is any material nonpublic information (“MNPI”) about the Company when determining the timing of stock option grants and does not seek to time the award of stock options in relation to our public disclosure of MNPI. We have not timed the release of MNPI for the purpose of affecting the value of executive compensation.
|
||
| Award Timing Method | From time to time, we grant stock options to employees, including our named executive officers. Historically, we have granted new-hire option awards on or soon after a new hire’s employment start date and annual refresh employee option grants in the first quarter of each fiscal year, which refresh grants are typically approved at the regularly scheduled meeting of the Compensation Committee occurring in such quarter. Non-employee directors receive automatic grants of initial and annual stock option awards, at the time of a director’s initial appointment or election to the board and at the time our Board or Compensation Committee grants annual equity awards to our executive officers and other employees, respectively, pursuant to the non-employee director compensation policy, as further described under the heading, “Director Compensation—Cash and Equity Compensation” above. We do not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features. The Compensation Committee considers whether there is any material nonpublic information (“MNPI”) about the Company when determining the timing of stock option grants and does not seek to time the award of stock options in relation to our public disclosure of MNPI. We have not timed the release of MNPI for the purpose of affecting the value of executive compensation.
|
||
| Award Timing Predetermined | true | ||
| Award Timing MNPI Considered | true | ||
| Award Timing, How MNPI Considered | The Compensation Committee considers whether there is any material nonpublic information (“MNPI”) about the Company when determining the timing of stock option grants and does not seek to time the award of stock options in relation to our public disclosure of MNPI. We have not timed the release of MNPI for the purpose of affecting the value of executive compensation. | ||
| MNPI Disclosure Timed for Compensation Value | false | ||
| Margaret Alexander [Member] | Employee Stock Option | |||
| Awards Close in Time to MNPI Disclosures | |||
| Name | Margaret Alexander | Margaret Alexander | |
| Underlying Securities | shares | 140 | 315 | |
| Exercise Price | $ / shares | $ 1.07 | $ 1.05 | |
| Fair Value as of Grant Date | $ | $ 118,860 | $ 258,394 | |
| Underlying Security Market Price Change | 0.009 | (0.030) | |
| Jeffrey Rona [Member] | Employee Stock Option | |||
| Awards Close in Time to MNPI Disclosures | |||
| Name | Jeffrey Rona | ||
| Underlying Securities | shares | 315 | ||
| Exercise Price | $ / shares | $ 1.05 | ||
| Fair Value as of Grant Date | $ | $ 258,394 | ||
| Underlying Security Market Price Change | (0.030) |
Insider Trading Policies and Procedures |
12 Months Ended |
|---|---|
Dec. 31, 2024 | |
| Insider Trading Policies and Procedures [Line Items] | |
| Insider Trading Policies and Procedures Adopted | true |